Forty Seven, Inc. (OTC:FTSV)
Industry: PharmaceuticalsMajor

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Current Quote*
Last: $15.617
Change: 0.087
Book: $3.222
Volume: 85,252

As Of: 02/15 13:36 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol FTSV

Graphs for FTSV


3 Month Graph


6 Month Graph


1 Year Graph